Drug Safety Research Unit (DSRU) plans ‘post-authorisation’ study of COVID-19 vaccines in the UK

According to the DSRU, this post-authorisation study will aim to capture the reporting by vaccinees and enable near real-time evaluation and communication of potential side effects, thus providing the public with reassurance that the vaccines are under continuous monitoring.

Source:

PharmaTimes